Microbot Medical (MBOT) Cash & Equivalents (2010 - 2026)

Microbot Medical has reported Cash & Equivalents for 17 years, with the latest figure at $68.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 143322.92% year-over-year to $68.8 million; the trailing twelve-month figure through Mar 2026 stood at $68.8 million (up 143322.92% YoY), and the FY2025 full-year result was $3.9 million, up 25.63% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $68.8 million, up from $3.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $68.8 million in Q1 2026, with the low at $46000.0 in Q3 2023.
• Historically, Cash & Equivalents has averaged $6.0 million across 5 years, with a median of $2.2 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 99.53% — and 2026, when it surged 143322.92%.
• Microbot Medical's Cash & Equivalents stood at $2.4 million in 2022, then grew by 1.06% to $2.5 million in 2023, then grew by 26.18% to $3.1 million in 2024, then gained by 25.63% to $3.9 million in 2025, then jumped by 1659.79% to $68.8 million in 2026.
• The last three Cash & Equivalents figures came in at $68.8 million (Q1 2026), $3.9 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.